Climb Bio reports early data on budoprutug for kidney diseases
What it means
- What to watch: Good trial results are only step one; approval timing and pricing decide how much it is worth.
- How the stock is trading: $CLYM -3.32% in the latest session.
- Timing: It landed over the weekend, while the market was off the clock: the change beside it is Friday's, and Monday is the first session that could react. Market holidays are not detected.
Where the stock stands
$CLYM last traded at $10.19, -3.32% on the session. That puts it 44% shy of its 52-week high of $18.33 and 523% clear of its low of $1.64 — around the middle of the range. Over the year it has ranged 1021% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $CLYM page.
How much coverage it is getting
Nothing else on $CLYM in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$CLYM earnings in 11 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
The $CLYM page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $CLYM sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. It reads bullish at medium severity because of “climb” in the wording, with nothing on the bearish side to offset it. It was matched to $CLYM. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.